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OBJECTIVE — Toevaluatethelong-termprognosisofcriticallimbischemia(CLI)indiabetic
patients.
RESEARCH DESIGN AND METHODS — A total of 564 consecutive diabetic patients
were hospitalized for CLI from January 1999 to December 2003; 554 were followed until
December 2007.
RESULTS — The mean follow-up was 5.93  1.28 years. Peripheral angioplasty (PTA) was
performedin420(74.5%)andbypassgraft(BPG)in117(20.6%)patients.NeitherPTAnorBPG
were possible in 27 (4.9%) patients. Major amputations were performed in 74 (13.4%) patients:
34 (8.2%) in PTA, 24 (21.1%) in BPG, and 16 (59.2%) in a group that received no revascular-
ization.Restenosisoccurredin94patients,bypassfailuresin36patients,andrecurrentulcersin
71 patients. CLI was observed in the contralateral limb of 225 (39.9%) patients; of these, 15
(6.7%)requiredmajoramputations(rateincontralateralcomparedwithinitiallimb,P0.007).
Attotalof276(49.82%)patientsdied.TheCoxmodelshowedsigniﬁcanthazardratios(HRs)for
mortality with age (1.05 for 1 year [95% CI 1.03–1.07]), unfeasible revascularization (3.06
[1.40–6.70]), dialysis (3.00 [1.63–5.53]), cardiac disease history (1.37 [1.05–1.79]), and im-
paired ejection fraction (1.08 for 1% point [1.05–1.09]).
CONCLUSIONS — Diabetic patients with CLI have high risks of amputation and death. In
adedicateddiabeticfootcenter,themajoramputation,ulcerrecurrence,andmajorcontralateral
limbamputationrateswerelow.Coronaryarterydisease(CAD)istheleadingcauseofdeath,and
in patients with CAD history the impaired ejection fraction is the major independent prognostic
factor.
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A
variety of consensus statements
andreviews(1–3)haveassessedthe
outcomes of diabetic patients with
peripheral arterial disease (PAD). How-
ever, we are not aware of any prospective
studies performed in a diabetic popula-
tion with critical limb ischemia (CLI).
The aim of this prospective study was to
evaluate in diabetic patients the prog-
nostic impact of CLI diagnosed accord-
ing to the criteria proposed in 2000 by
the Transatlantic Inter-Society Consen-
sus (TASC) (4).
RESEARCH DESIGN AND
METHODS— Between 1 January
1999 and 31 December 2003, 564 dia-
betic patients were hospitalized in our di-
abetic foot center because of CLI. During
the hospital stay, patients and their fami-
liesweretrainedtomanagebothanulcer-
ated and a nonulcerated foot. The
importance of prompt immediate referral
to our center, irrespective of scheduled
visits, was pointed out in cases of insur-
genceofischemicrestpainorulcerations,
even of minimal appearance. All patients
who underwent peripheral revasculariza-
tion were prescribed either 250 mg/day
ticlopidine plus 100 mg/day salicylic acid
or 500 mg/day ticlopidine.
CLI diagnosis
All diabetic patients referred to our dia-
betic foot center for ischemic rest pain
and/or foot ulcer or gangrene were as-
sessed for the presence of sensory motor
neuropathy, infection, and CLI. Sensory
motor neuropathy was diagnosed in pa-
tients with a biothesiometer vibration
perceptionthreshold25V,insensitivity
to touching with a Semmes-Weinstein
10-g ﬁlament in 5 of 9 foot points, and
absence of the Achilles tendon reﬂex. In
patients with foot ulcers, the presence of
an infection was indicated by local cellu-
litis, erythema, or purulence with a posi-
tive swab culture. CLI was diagnosed in
patients with 70 mmHg ankle pressure,
when assessable, and 50 mmHg trans-
cutaneous oxygen tension (TcPO2)a tt h e
dorsum of the foot.
Vascular procedures
All patients with CLI were referred to an
angiographic study. Patients with vessel
diameter obstruction 50% underwent
peripheral angioplasty (PTA) during the
angiographic study, when possible, as a
ﬁrst-choice revascularization procedure
(PTA group) (5). PTA was utilized exten-
sively: no stenosis or occlusion was con-
sidered a priori unsuitable for a PTA
recanalization. Stenoses or occlusions
10 cm in length and consecutive multi-
ple stenoses (types C and D of the TASC
morphological stratiﬁcation of obstruc-
tions) were treated with PTA when possi-
ble; PTA was not feasible when calciﬁed
vessel occlusions did not permit passage
of a balloon catheter. Vessel recanaliza-
tion was considered successful when di-
rect ﬂow was achieved in at least one
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signiﬁcant residual stenoses along the en-
tire artery.
When PTA was not feasible, a bypass
graft (BPG) was considered (BPG group).
BPGwasperformedusinganintraluminal
clamping and microsurgical technique.
Theautogenoussaphenousveinwasused
for grafting when present and in good
condition. When it was not available, al-
loplastic prosthetic material (polytetra-
ﬂuoroethylene [PTFE]) was utilized and
the peripheral anastomosis consisted of a
venouscuff.Thus,theabsenceofanavail-
able saphenous vein and an angiographic
score run off 7 on the Rutherford scale
(6) did not exclude patients from a revas-
cularization with a distal bypass; other-
wise, the only recourse for those patients
would have been a major amputation.
When neither PTA nor BPG were possi-
ble, patients received prostanoid therapy
(60–120 g/day alprostadil--ciclodex-
trine) over a period of 5 days after the
angiography.
Hemodynamic improvement
TcPO2 values were reassessed 5–10
days after the PTA, BPG, or prostanoid
infusion.
End points
The following end points were recorded:
above-the-ankle amputation, ulcer recur-
rence, clinical restenosis after PTA, BPG
failure,CLI,majoramputationinthecon-
tralateral limb, and survival.
Amputation
Limb salvage was considered successful
when the plantar stance was maintained,
even when achieved by tarsal-metatarsal
amputation (7). Conversely, any above-
the-ankle amputation was considered a
major amputation, and it was deemed a
failure. It was performed when therapies
did not relieve patients from resting pain
or when gangrene had extended beyond
the Chopart joint.
Restenosis after PTA
Restenosis was suspected when ischemic
restpainreappearedoranulcerworsened
or did not heal. In these situations, ankle
pressure and TcPO2 were reassessed and
duplexscanningwasperformed(8).Ifan-
kle pressure and TcPO2 again showed
values diagnostic for CLI and had signiﬁ-
cantly deteriorated (15% of the post-
PTA value) and Duplex scanning was
positive, a further PTA was performed.
When a PTA was not possible, a BPG was
considered. Morphological restenoses
werenotinvestigated;wedidnotperform
revascularizations in the absence of isch-
emic resting pain or ulcerations; there-
fore, we considered morphological
restenoses clinically irrelevant (9).
BPG failure
Vascular surgeons assessed graft patency
by ultrasonography at 30 days; 3, 6, and
12months;andevery6monthsthereafter
(10).
Ulcer recurrence
The reappearance of a foot lesion after the
primary ulcer had healed was considered
an ulcer recurrence.
Vital status and cause of death
The vital status of all 554 patients was
determinedattheendoffollow-up.Dates
and causes of deaths were recorded. All
patientsinourstudypopulationhadbeen
referred to our diabetic foot center from
other diabetes centers. After admission
due to CLI, they were moved to the orig-
inating diabetes center for diabetologic
and comorbid condition treatments.
Database
The database records included age, sex,
diabetes treatment and duration, glyce-
mia (ﬁnger-stick glucose) at entry and
discharge, A1C (with high-pressure liq-
uid chromatography; normal value
4–6.4%), albumin excretion (mg/24 h;
nephelometry; Behring, Scopito, Italy),
serum creatinine value (mg/dl, Jaffe;
Roche,Milan,Italy),arterialhypertension
(antihypertensive treatment), history of
cardiac disease, ejection fraction (evalu-
atedwithtransthoracicechocardiography
in patients with a history of cardiac dis-
ease), history of stroke, and history of
prior major amputation.
Statistical methods
DataweregivenasaveragevaluesandSDs
forcontinuousvariablesoraspercentages
for discrete variables. We explored the
role of continuous variables across the
treatment groups with the Student’s t test
and ANOVA. The presence of prognostic
factors was assessed with the 
2 test with
Yate’s correction. The 95% CI was
adopted, and 5% was considered signiﬁ-
cant for the null hypothesis. The propor-
tionofsurvivingpatientswasplottedwith
a Kaplan-Meier curve, and differences in
survival among subgroups were tested by
the log-rank test. Cox’s proportional haz-
ards model was used to select signiﬁcant
prognostic factors. Proportionality
among the survival rates and attributable
factors in the Cox model was assessed by
plotting the log(log [survival function])
versus time in each subgroup. The signif-
icantroleofcovariateswasmeasuredwith
the likelihood ratio test, and the role of
each covariate entering the model was as-
sessed by the Wald statistic. Statistical
analyses were performed with STATA 9.0
for Windows. Analysis of survival was
carried out on an intention-to-treat basis.
RESULTS
Of the initial 564 patients, 554 (98.2%)
were followed until 31 December 2007
for a mean of 5.93  1.28 years. Of the
554 followed patients, 413 (74.5%) un-
derwent PTA and 114 (20.6%) under-
went BPG in the initially affected limb. In
the remaining 27 (4.9%) patients, neither
PTA nor BPG could be performed (non-
revascularized patients).
Demographics and clinical character-
istics of the three groups are reported in
Table 1. The ankle pressure could not be
measured in 297 (53.6%) patients due to
the occlusion of both tibial arteries in 105
and due to the presence of arterial calciﬁ-
cations in 192 patients (11). Toe pressure
could not be measured in 89 patients due
to a previous amputation or gangrene on
the big toe. Thus, ankle and toe pressure
parameters were not considered in the
data analysis.
PTA was performed in 413 (74.5%)
patients. In these patients, angiography
revealed obstructions 50% of vessel di-
ameter exclusively located in the iliac-
femoral-popliteal axes in 28 patients
(6.8%) and exclusively located in the in-
frapopliteal axis in 137 subjects (32.2%).
Obstructionswerefoundinboththeiliac-
femoral-popliteal and infrapopliteal axes
in248patients(60.0%).ThemeanTcPO2
values were 15.3  11.9 mmHg before
and 44.9  12.1 mmHg after PTA (P 
0.001). A BPG was performed in 114
(20.6%)patients.TheRutherfordgrading
for runoff was 6.4  2.6. The BPG was
axillo-femoral in one patient, femoral-
popliteal (15 PTFE, 44 vein graft) in 58
patients, and femoral-infrapopliteal (16
PTFE, 39 vein graft) in 55 patients. The
mean TcPO2 values were 10.2  10.3
mmHg before and 38.8  11.9 mmHg
after BPG (P  0.001).
NeitheraPTAnoraBPGwaspossible
in 27 (4.8%) patients due to high surgery
risk (7 patients) or lack of outﬂow (20
patients). These patients received prosta-
noidstreatmentfor5daysduringthehos-
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TcPO2 values were 7.0  8.1 mmHg be-
fore and 11.4  8.6 mmHg after prosta-
noid treatment (P  0.055). After
revascularization, no signiﬁcant differ-
encewasobservedintheTcPO2valuesfor
the PTA and BPG groups (P  0.690). In
contrast, a signiﬁcant difference was ob-
served between revascularized and non-
revascularized patients (P  0.001).
Minor amputation
Atotalof440revascularizedpatientswith
foot ulcers showed complete healing of
the lesions: 93 patients did not receive
any minor amputations (35 patients by
means of foot dressings, 12 bone remov-
als, 16 ulcerectomies, and 30 skin
grafts). A total of 93 patients had toe or
ray amputations, and 254 patients had
tarsal-metatarsal amputations. Of 13
nonrevascularized patients who did not
receive major amputations, 10 had foot
ulcers. Two showed complete healing
withadressing,andeightpatientsdidnot
show healing or worsening. All 13 of the
nonrevascularized patients experienced
reduced pain that did not disappear, and
analgesicmedicationwasreducedbutnot
discontinued.
Major amputation
A total of 74 (13.4%) patients received
major amputations, 23 in the early period
and 51 during follow-up (total incidence
per year: 3.72%).
After PTA, six major amputations
wererequiredwithin30daysand28were
performed during follow-up, with an in-
cidenceperyearof2.3%.AfterBPG,three
major amputations were required within
30 days and 21 were performed during
follow-up, with an incidence per year of
5.4%.Forpatientswhoreceivednorevas-
cularization, 14 major amputations were
required within 30 days and two during
follow-up, with an incidence per year of
34.3%.
At 30 days, there was no signiﬁcant
difference in the major amputation rates
of PTA and BPG groups (P  0.414), but
during the follow-up, there was a signiﬁ-
cant difference (P  0.001). There were
highly signiﬁcant differences in the major
amputation rates of the two groups (re-
vascularized and not revacularized), both
in the early period (
2  162.6054, P 
0.001) and during follow-up (
2 
64.3614, P  0.001).
Multivariate analysis of the variables
that were found to be associated in the uni-
variate analysis conﬁrmed the independent
roles of no revascularization (odds ratio
35.9 [95% CI 12.9–99.7], P  0.001), oc-
clusion of each of the crural arteries (8.20
[1.35–49.6], P  0.022), dialysis (4.7
[1.9–11.7], P  0.001), and wound infec-
tion (2.1 [1.3–3.6], P  0.004). The analy-
sis shows that a high TcPO2 value after the
treatmenthasaprotectiveeffect(0.8[0.74–
0.87], P  0.001).
PTA restenosis
After the PTA, a total of 127 clinical reste-
noses occurred in 94 patients (incidence
Table 1—Demographic and clinical characteristics of study population (n  554) at the study entry in nonrevascularized and revascularized
patients with PTA or BPG
Variables PTA group BPG group P
Revascularization
group
No
revascularization
group P
n 413 114 527 27
Age (years) 69.7  9.5 69.9  9.4 0.910 69.8  9.5 76.7  10.4 0.001
Females 146 (35.4) 35 (30.7) 0.737 181 (34.3) 13 (48.1) 0.152
Insulin therapy 254 (61.5) 73 (64.0) 0.664 327 (62.2) 14 (51.9) 0.314
Diabetes duration (years) 17.7  11.4 14.9  9.9 0.020 17.1  11.1 13.4  10.0 0.013
Glycemia (at entry) (mg/dl) 177.9  72.9 187.6  9.7 0.187 180.7  71.8 177.7  52.3 0.147
Glycemia (at discharge) (mg/dl) 139.6  47.3 134.2  43.7 0.082 138.1  45.5 138.2  63.1 1.126
A1C (%) 7.6  1.7 7.8  1.5 0.625 7.7  1.6 7.5  1.1 0.579
Sensory motor neuropathy 340 (82.3) 92 (80.7) 0.681 441 (82.1) 24 (88.9) 0.599
Albumin excretion (mg/l) (n  522) 259.8  529.7 283.9  721.3 0.832 264  559.9 251.6  363.6 0.932
Creatinine (mg/dl) (n  522) 1.29  0.5 1.25  0.4 0.470 1.28  0.5 1.15  0.36 0.208
Dialysis 24 (5.7) 8 (7.0) 0.650 32 (6.0) — —
Antihypertensive therapy 298 (72.2) 72 (63.2) 0.065 370 (70.2) 20 (74.1) 0.830
History of cardiac disease 225 (54.8) 64 (59.0) 0.566 289 (53.8) 24 (88.9) 0.003
Ejection fraction (n  313) 49.1  10.8 49.6  10.1 0.700 49.2  10.5 38.34  8.4 0.001
History of stroke 53 (18.8) 18 (15.8) 0.439 71 (13.8) 9 (33.3) 0.009
Smokers 61 (14.8) 19 (16.7) — — —
Total cholesterol (mg/dl) 181.2  43.6 188.0  42.6 0.943 183.0  43.1 186.7  41.8 0.992
HDL cholesterol (mg/dl) 42.1  13.6 43.7  11.2 0.978 42.6  13.1 48.6  19.8 0.070
Triglycerides (mg/dl) 143.6  87.6 137.6  61.9 0.838 142.7  81.1 149.4  175.1 0.762
Wagner grade 0 62 (16.0) 16 (14.0) 0.882 78 (14.8) 3 (11.0) 0.783
Wagner grade 1 63 (15.3) 14 (12.3) 0.549 77 (14.6) 5 (18.5) 0.578
Wagner grade 2 59 (14.3) 14 (12.3) 0.648 73 (13.9) 5 (18.5) 0.567
Wagner grade 3 41 (9.9) 11 (9.6) 1.000 52 (9.9) 3 (11.1) 0.743
Wagner grade 4 188 (45.6) 59 (51.8) 0.245 247 (46.9) 11 (40.7) 0.560
Infected ulcer 268 (64.9) 72 (63.2) 0.741 340 (64.5) 17 (63.0) 0.892
Ischemic rest pain 309 (74.8) 92 (80.7) 0.216 401 (76.1) 25 (92.6) 0.059
Data are means  SD or n (%).
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was made in 100 case subjects based on
the lack of wound healing, with or with-
outpain,andin27casesubjectsbasedon
thereappearanceofrestingpainwithouta
foot lesion. The resulting ischemic limb
was further revascularized in 81 patients;
72 patients underwent a further PTA and
9 patients underwent a BPG. These pro-
cedures were not practicable in the re-
maining 13 patients; thus, a major
amputation was required. After the fur-
ther PTA, 29 patients required further
surgical intervention due to diastasis of
the surgical wound.
BPG failure
A total of 36 BPG failures were observed
(incidence per year: 8.8%). Fifteen of
these received a PTA or further BPG.
Twenty-one patients who could not sus-
tain further revascularization either by
PTA or BPG required major amputations.
In all 21 patients, the major amputation
wasperformedduetothereappearanceof
ischemic rest pain with or without ulcers.
After recanalization of the graft, two pa-
tients also required a further surgical in-
tervention due to diastasis of the surgical
wound.
Ulcer recurrence
A total of 71 patients were readmitted to
ourhospitalduetoulcerrecurrencewith-
out evidence of CLI (incidence per year:
4.3%). The Wagner grades of these ulcers
were 1 for 57 patients, 2 for 11 patients,
and 4 for 3 patients. All the lesions healed
without the need for a major amputation;
7 patients required toe amputations and
64 patients required no minor amputa-
tions.Noulcerrecurrenceswereobserved
in patients who had PTA restenoses or
BPG failures during follow-up.
CLI incidence and amputation in the
contralateral limb
CLI in the contralateral limb was ob-
servedin225(40.6%)patients(incidence
per year: 14.76%). A major contralateral
limb amputation was performed in 15
(6.7%) patients. The amputation rate was
signiﬁcantly lower in the contralateral
limb compared with that in the limb that
had the initial CLI (
2  7.3, P  0.007).
Survival
A total of 276 (49.8%) patients died, 4 at
30 days and 272 during follow-up, with
an incidence per year of 12.53%. Table 2
reports the causes of death.
The annual death incidence was not
different between patients who received
PTA (n  202; 48.9%) and those who
received BPG (n  51, 44.7%; 
2 0.74,
P  0.391). The annual death incidence
inpatientswhoreceivedperipheralrevas-
cularization (11.9%) was different from
thatinpatientswhodidnotreceiverevas-
cularization(52.9%;
253.6,P0.001).
Figure 1 shows the Kaplan-Meier major
amputation and survival estimates for pa-
tients who received PTA, BPG, or no re-
vascularization. Cardiac disease was the
leading cause of death, with an annual
incidence rate of 8.1%. Cardiac disease
was due to acute myocardial infarction in
89 (49.7%), pump failure in 72 (40.0%),
and sudden death in 18 (10.1%) patients.
Multivariate analysis of the variables
that were found to be associated in the
univariate analysis conﬁrmed the inde-
pendentrolesofage(hazardratio1.05for
1 year, P  0.001, 95% CI 1.03–1.07),
unfeasible peripheral revascularization
(3.06, P  0.005, 1.40–6.70), dialysis
(3.00,P0.001,1.63–5.53),andhistory
of cardiac disease (1.37, 1.05–1.79). In
patients with history of cardiac disease,
impaired ejection fraction was indepen-
dently associated with death (1.08 for 1%
point, P  0.001, 1.05–1.09).
CONCLUSIONS— PADisanunder-
recognized complication of diabetes (12).
CLI is an even more underrecognized
complication (13,14). For diabetic pa-
tients,theonsetofCLIisadramaticevent;
the risk of major amputation and death is
considerable. The proper management of
CLI could improve the amputation out-
come. Compared with the data reported
in the literature, our series of revascular-
ized patients required decidedly fewer
major amputations in both the early and
follow-upperiods(15).Thisismostlikely
due to the ability of our diabetic foot cen-
ter to perform both endoluminal and sur-
gical revascularization techniques, thus
providing 95% of the patients with ves-
sel revascularization. The rate of amputa-
tion was consistently lower in patients
that received revascularization compared
with patients that could not undergo re-
vascularization (16). Moreover, the am-
putation rate would certainly have been
higher if the latter group of patients had
not had such a high mortality rate. Nev-
ertheless,thecenter’soptimalcapacityfor
revascularization is not enough to reduce
the rate of major amputations. An excel-
lent diagnostic ability and an adequate
ulcer management program postrevascu-
larization are also required (17).
Recentreportsintheliterature,andin
particular the recent Cochrane review,
have reported that surgical and endolu-
minal revascularizations had similar out-
comes in terms of mortality and major
amputation rates (18,19). We also ob-
served similar amputation rates for the
two procedures in the early period, but
during the follow-up, the BPG group had
a higher amputation rate than the PTA
group. The difference appeared in the
Kaplan-Meiercurvesatthelatefollow-up.
The only signiﬁcantly different parameter
between the two groups at admission was
the TcPO2. However, in our protocol, the
BPG was performed only when PTA was
impossible; this may have selected pa-
tientswithmoreseverearteriopathy.Nev-
ertheless, the most important message
that emerged from this study regarding
the treatment of diabetic patients with
CLI was the enormous difference in the
amputation rate between patients that re-
ceived and those that did not receive re-
vascularization; this difference was
evident in both the early and the late fol-
low-up periods. This showed that a suc-
cessful revascularization was more
important than the type of revasculariza-
tion used.
Readmission to the hospital occurred
frequently due to late failure of revascu-
larization (because of restenosis after PTA
or because of failure of BPG). We found
thatantiplatelettherapyplayedanimpor-
tant role in both PTA restenosis and BPG
failure (i.e., we frequently found that pa-
tients had been prescribed insufﬁcient
doses of ticlopidine). However, many pa-
tients, particularly those who developed
Table 2—Causes of death in the followed
population (n  554)
Cause of death
n 276
Cardiac disease 179 (64.9)
Stroke 35 (12.7)
Cancer 28 (10.1)
Pulmonary embolism 4 (1.4)
Aneurysm 2 (0.7)
Renal insufﬁciency 6 (2.2)
Gastroenteric disease 4 (1.4)
Cirrhosis 5 (1.8)
Pneumonia 4 (1.4)
Geromarasmus 7 (2.5)
Septic shock 1 (0.4)
Suicide 1 (0.4)
Data are n (%).
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vascularization that enabled them to
avoid amputation. These events contrib-
uted to the high number of hospitaliza-
tions required to minimize the rate of
major amputation. Our data fully agree
with other authors who also found that
this population required multiple proce-
dures and admissions (20).
Incidenceofulcerrecurrencewaslow
(	13% over 6 years) in this study com-
pared with that reported in the literature
(estimated at 50% over 2–5 years) (21).
We believe that this low recurrence was
achieved due to the instructions given to
the patients, the relationships established
between the caregivers and the patient,
and the protection of therapeutic shoes
(22).
Almost half of our study population
developed CLI in the contralateral limb
over an 	6-year period. Data from the
literature are rather scarce regarding the
fate of the contralateral limb in a diabetic
population with prior CLI in one limb. A
few studies published in the early 2000s
reported surveys on the fate of contralat-
eral limbs in patients selected for major
amputations of the initially affected limb,
patients with mixed ulcers, or patients
with either neuropathy or ischemia (23).
Apart from the epidemiological value of
ourdataontheincidenceofCLI,ourﬁnd-
ing that there was signiﬁcantly lower fre-
quency of above-the-ankle amputations
in contralateral limbs compared with that
of initially affected limbs is predicted to
haveahighimpactonthemanagementof
CLIindiabeticpatients.Thisresultshows
that early recognition of the pathology
and prompt referral of patients to the di-
abetic foot center allowed commence-
ment of treatment under conditions more
favorable for combating CLI. Thus, the
prognosis for the contralateral limb was
more promising than that for the initially
affected limb.
Itiswell-knownthatdeathassociated
with cardiac disease occurs considerably
more frequently than amputation in dia-
betic and nondiabetic patients affected by
PAD. It also is well known that life ex-
pectancy is negatively correlated to the
severity of the arteriopathy (24). Thus,
considering thelate onset of CLI, it is not
surprising that age had an independent
prognosticvalueonlifeexpectancyinthis
study (25). It may have been possible to
increase the survival rate in these patients
if, during the hospitalization for CLI, we
had considered improving existing coro-
nary artery disease (CAD) treatment or
evaluating the possibility of silent isch-
emia in patients without a history of car-
diac disease. In the future, ad hoc studies
will be necessary investigate this question.
Data of this series suggest that aggres-
sive treatment of CLI in diabetic patients,
as practiced in our diabetic foot center,
made it possible to achieve a low rate of
major amputation in the initially af-
fectedlimbandanevenlowerrateinthe
contralateral limb. CAD was the main
cause of death, and in patients with his-
tory of CAD, the impaired ejection
fraction was the major independent
prognostic factor.
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